JPWO2022044573A1 - - Google Patents

Info

Publication number
JPWO2022044573A1
JPWO2022044573A1 JP2022545513A JP2022545513A JPWO2022044573A1 JP WO2022044573 A1 JPWO2022044573 A1 JP WO2022044573A1 JP 2022545513 A JP2022545513 A JP 2022545513A JP 2022545513 A JP2022545513 A JP 2022545513A JP WO2022044573 A1 JPWO2022044573 A1 JP WO2022044573A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022545513A
Other languages
Japanese (ja)
Other versions
JPWO2022044573A5 (https=
JP7773154B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022044573A1 publication Critical patent/JPWO2022044573A1/ja
Publication of JPWO2022044573A5 publication Critical patent/JPWO2022044573A5/ja
Application granted granted Critical
Publication of JP7773154B2 publication Critical patent/JP7773154B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
JP2022545513A 2020-08-26 2021-07-09 コロナウイルススパイク蛋白に対するヒト抗体またはその抗原結合断片 Active JP7773154B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020143055 2020-08-26
JP2020143055 2020-08-26
JP2021054387 2021-03-26
JP2021054387 2021-03-26
PCT/JP2021/026053 WO2022044573A1 (ja) 2020-08-26 2021-07-09 コロナウイルススパイク蛋白に対するヒト抗体またはその抗原結合断片

Publications (3)

Publication Number Publication Date
JPWO2022044573A1 true JPWO2022044573A1 (https=) 2022-03-03
JPWO2022044573A5 JPWO2022044573A5 (https=) 2023-06-20
JP7773154B2 JP7773154B2 (ja) 2025-11-19

Family

ID=80353115

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022545513A Active JP7773154B2 (ja) 2020-08-26 2021-07-09 コロナウイルススパイク蛋白に対するヒト抗体またはその抗原結合断片

Country Status (4)

Country Link
US (1) US20230312689A1 (https=)
EP (1) EP4206224A4 (https=)
JP (1) JP7773154B2 (https=)
WO (1) WO2022044573A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115073594A (zh) * 2022-06-08 2022-09-20 四川大学华西医院 一种抗新冠病毒SARS-CoV-2突变株表面S2蛋白的单链抗体、制备方法及其应用
WO2024053719A1 (ja) 2022-09-08 2024-03-14 国立大学法人熊本大学 コロナウイルス変異株に対するヒト抗体またはその抗原結合断片
CN118406139A (zh) * 2022-09-30 2024-07-30 郴州市第一人民医院 一种抗新型冠状病毒SARS-CoV-2的广谱中和抗体及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
CA2595780A1 (en) 2005-02-08 2006-08-17 Shibo Jiang Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
MX2008014710A (es) 2006-05-19 2009-02-12 Amgen Inc Anticuerpos para coronavirus del sars.
KR20250107297A (ko) * 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
CN111647076B (zh) * 2020-04-27 2021-02-26 南京医科大学 抗新型冠状病毒SARS-Cov-2的中和性单域抗体及其应用
CN111718411B (zh) * 2020-06-19 2022-03-08 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的单克隆抗体1F2
CN112521494B (zh) * 2020-06-19 2021-06-25 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的单克隆抗体2B11
CN111909261B (zh) * 2020-08-19 2022-10-04 重庆医科大学 新冠病毒rbd特异性单克隆抗体和应用
WO2022155324A1 (en) * 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAO, Y. ET AL.: "Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequenci", CELL, vol. 182, JPN6021032307, 9 July 2020 (2020-07-09), pages 73 - 84, ISSN: 0005591985 *
JU, B. ET AL.: "Human neutralizing antibodies elicited by SARS-Cov-2 infection", NATURE, vol. 584, JPN6021032313, 6 August 2020 (2020-08-06), pages 115 - 119, ISSN: 0005591988 *
LIU, L. ET AL.: "Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike", NATURE, vol. 584, JPN6021032306, 20 August 2020 (2020-08-20), pages 450 - 456, ISSN: 0005591984 *
SHI, R. ET AL.: "A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2", NATURE, vol. 584, JPN6021032312, 6 August 2020 (2020-08-06), pages 120 - 124, ISSN: 0005591987 *
WAN, J. ET AL.: "Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection", CELL REPORTS, vol. Vol.32, 107918, JPN6021032310, 21 July 2020 (2020-07-21), pages 1 - 8, ISSN: 0005591986 *

Also Published As

Publication number Publication date
WO2022044573A1 (ja) 2022-03-03
EP4206224A4 (en) 2025-04-02
EP4206224A1 (en) 2023-07-05
US20230312689A1 (en) 2023-10-05
JP7773154B2 (ja) 2025-11-19

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JPWO2022065445A1 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021014056A2 (https=)
BR102021014044A2 (https=)
BR102021013929A2 (https=)
BR102021012571A2 (https=)
BR102021012230A2 (https=)
BR102021012107A2 (https=)
BR102021012003A2 (https=)
BR112021013417A2 (https=)
BR102021010467A2 (https=)

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A5211

Effective date: 20230224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250513

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250911

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251029

R150 Certificate of patent or registration of utility model

Ref document number: 7773154

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150